<?xml version="1.0" encoding="UTF-8"?>
<p id="p0055">Importantly, some clinical findings in China have shown that Tocilizumab (a monoclonal anti-IL-6 receptor) can significantly improve oxygenation and may be considered a promising therapeutic option in patients with COVID-19 who are at the risk of cytokine storm (
 <xref rid="bib33" ref-type="bibr">33</xref>). Another small sample clinical trial in China has indicated good efficacy of Tocilizumab treatment in severe COVOD-19 patients (
 <xref rid="bib34" ref-type="bibr">34</xref>). A case report from France reported successful treatment of Covid-19-related respiratory failure using Tocilizumab in a patient with cancer (
 <xref rid="bib35" ref-type="bibr">35</xref>). According to previous studies, Tocilizumab can reduce the affinity of IL-6R to IL-6 by binding to IL-6R and soluble IL-6R, thereby inhibiting the CSS (
 <xref rid="bib18" ref-type="bibr">18</xref>). Tocilizumab as a recombinant humanized monoclonal antibody has been approved for the treatment of patients with severe CSS (
 <xref rid="bib36" ref-type="bibr">36</xref>,
 <xref rid="bib37" ref-type="bibr">37</xref>).
</p>
